NAD+: Safety Profile & Research Summary
$103.95 · COA do lote publicado · Água BAC grátis + frete grátis nos EUA · Despacho no mesmo dia antes das 14h ET · APENAS PARA USO EM PESQUISA
Comprar NAD+ 1000mgResumo da Pesquisa Pre-clinica
Key Preclinical Studies
| Estudo | Modelo | Principais Achados | Ref |
|---|---|---|---|
| Mills et al. (2016) | C57BL/6N mice — NMN 100–300 mg/kg/day oral × 12 mo | Suppressed weight gain ~10% (p<0.001); aumentou energy expenditure; melhorou sensibilidade a insulina; no obvious toxicity | [17] |
| Das et al. (2018) | Elderly C57BL/6 mice — NMN 500 mg/kg/day oral × 28d | Capillary density restaurou to young-mouse levels; endurance melhorou 80% via SIRT1-dependent vascular rejuvenation | [14] |
| Hou et al. (2018) | 3xTgAD Alzheimer's mice — NMN 100 mg/kg × 28d–3mo | Decreased Aβ oligomers; restaurou spatial memory in water maze tasks | [2] |
| Zhang et al. (2016) | Aged C57BL/6 mice — NR 400 mg/kg/day oral × ~6mo | Extended median lifespan 5% (p<0.05); aprimorou muscle stem cell function; aumentou grip strength | [9] |
| Cantó et al. (2012) | HFD mice — NR 400 mg/kg/day oral × 8–12 wk | Prevented weight gain (40% menos do que controls); aumentou thermogenesis | [11] |
| Ying/Won (2007/2012) | Rat isquemia — NAD+ 10–20 mg/kg × 2h post-injury | Reduced infarct volume (p<0.01); bypasses BBB; profound neuroprotecao | [15] |
| Tarragó et al. (2018) | Aged mice (32 mo) — 78c (CD38 inhibitor) oral | Increased NAD+ in liver/muscle/heart; melhorou glucose tolerance | [8] |
Human Clinical Data: NMN Trials
| Ensaio | Population | Key Results | Ref |
|---|---|---|---|
| Christen et al. (2025) | n=65 adultos saudaveis | NAD+ and gut-microbial NA-intermediate endpoints | [4] |
| Yoshino et al. (2021) | n=25 prediabetic women | Muscle insulin-sensitivity endpoints | [10] |
| Pencina et al. (2023) | n=32 overweight 55–80y | NAD+ metabolite, body-weight and blood-pressure endpoints reported | [20] |
Human Clinical Data: NR Trials
| Ensaio | Population | Key Results | Ref |
|---|---|---|---|
| Trammell et al. (2016) | n=12 adultos saudaveis | NAD+ metabolome endpoints | [5] |
| Martens et al. (2018) | n=24 ages 55–79 | PBMC NAD+, blood-pressure and aortic-stiffness endpoints | [21] |
| Brakedal et al. (2022) — NADPARK | n=30 Parkinson's | Cerebral NAD+ and motor endpoints | [12] |
| Wang et al. (2022) | n=30 HFrEF | Blood NAD+, NLRP3 and cardiac-function endpoints | [22] |
| Wu et al. (2025) | Older adults with MCI | Plasma pTau217 endpoint | [13] |
| de la Rubia et al. (2019) | n=32 ALS | ALSFRS, pulmonary-function and strength endpoints | [23] |
Direct IV NAD+ Data
| Ensaio | Population | Key Results | Ref |
|---|---|---|---|
| Grant et al. (2019) | n=11 healthy men | Plasma and PBMC NAD+ endpoints | [24] |
Safety Summary
| Parametro | Finding |
|---|---|
| NR Safety | GRAS status; no serious AEs reported in trials up to 12 weeks |
| NMN Safety | No serious AEs reported in trials up to 12 weeks |
| Theoretical Risks | Tumorigenesis (not observado(a) in longo prazo animal studies); SARM1 axonal degeneration; metilacao depletion from excess NAM |
Os produtos oferecidos neste site são fornecidos apenas para estudos in vitro. Estudos in vitro (do latim: em vidro) são realizados fora do corpo. Estes produtos não são medicamentos ou fármacos e não foram aprovados pelo FDA dos EUA para prevenir, tratar ou curar qualquer condição médica, enfermidade ou doença. A introdução corporal de qualquer tipo em humanos ou animais é estritamente proibida por lei.
Apenas para Pesquisa Laboratorial. Não se destina ao uso humano, uso médico, uso diagnóstico ou uso veterinário.
TODOS OS ARTIGOS E INFORMAÇÕES SOBRE PRODUTOS FORNECIDOS NESTE SITE SÃO APENAS PARA FINS INFORMATIVOS E EDUCACIONAIS.
“Resumo da Pesquisa Pre-clinica Key Preclinical Studies EstudoModeloPrincipais AchadosRef Mills et al.”
Referencias
- Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolismo e seu(sua) roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141.
- Rajman L, Chwalek K, Sinclair DA. Cell Metabolism. 2018;27(3):529-547.
- Verdin E. NAD+ in aging, metabolismo, and neurodegeneration. Science. 2015;350(6265):1208-1213.
- Christen S, Redeuil K, Goulet L, et al. Nature Metabolism. 2025 Jan 15 [Epub].
- Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nature Communications. 2016;7(1):12948.
- Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends in Cell Biology. 2014;24(8):464-471.
- Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1 Toll/interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity que promove pathological axonal degeneration. Neuron. 2017;93(6):1334-1343.e5.
- Tarragó MG, Chini CCS, Kanamori KS, et al. Cell Metabolism. 2018;27(5):1081-1095.e10.
- Zhang H, Ryu D, Wu Y, et al. NAD+ repletion melhora mitochondrial and stem cell function and aprimora life span in mice. Science. 2016;352(6292):1436-1443.
- Yoshino M, Yoshino J, Kayser BD, et al. Science. 2021;372(6547):1224-1229.
- Cantó C, Houtkooper RH, Pirinen E, et al. Cell Metabolism. 2012;15(6):838-847.
- Brakedal B, Dölle C, Riber F, et al. Cell Metabolism. 2022;34(3):396-407.e6.
- Wu J, et al. Alzheimer's & Dementia: TRCI. 2025.
- Das A, Huang GX, Bonkowski MS, et al. Impairment of an endothelial NAD+-H₂S signaling network is a reversible cause of vascular aging. Cell. 2018;173(1):74-89.e20.
- Guan Y, Wang SR, Huang XZ, et al. Nicotinamide mononucleotide, an NAD+ precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent manner. Journal do(a) American Society of Nephrology. 2017;28(8):2337-2352.
- Liao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Journal do(a) International Society of Sports Nutrition. 2021;18(1):54.
- Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitiga age-associated physiological decline in mice. Cell Metabolism. 2016;24(6):795-806.
- Igarashi M, Nakagawa-Nagahama Y, Miura M, et al. npj Aging. 2022;8(1):5.
- Yi L, Maier AB, Tao R, et al. GeroScience. 2023;45(1):29-43.
- Pencina KM, Lavu S, Dos Santos M, et al. Journal of Clinical Endocrinology & Metabolism. 2023;108(4):862-871.
- Martens CR, Denman BA, Mazzo MR, et al. Nature Communications. 2018;9(1):1286.
- Wang DD, et al. Nicotinamide riboside in insuficiencia cardiaca with reduziu ejection fraction. JACC: Basic to Translational Science. 2022.
- de la Rubia JE, Drehmer E, Platero JL, et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2019;20(1-2):115-122.
- Grant R, Berg J, Mestayer R, et al. Frontiers in Aging Neuroscience. 2019;11:257.
- Yoshino J, Mills KF, Yoon MJ, Imai S. Cell Metabolism. 2011;14(4):528-536.
- Poljsak B, Kovač V, Špalj S, Milisav I. International Journal of Molecular Sciences. 2023;24(3):2959.
Perguntas de Pesquisa Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Deseja a revisao completa da pesquisa?
Comprar NAD+ 1000mg→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.
